Sascha-Oliver Bucher

Alentis Therapeutics, a Basel, Switzerland-based clinical-stage biotech company, raised $181.4M in Series D funding. The round was led by OrbiMed, with Novo Holdings and Jeito Capital with participation from Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital, Avego Bioscience Capital, RA Capital Management, Morningside Venture Investments, BB Pureos and BPI France through its InnoBio 2 fund. The company intends to use the funds to begin Phase 1/2 trials for two first-in-class ADCs: ALE.P02, which targets advanced or metastatic CLDN1+ squamous solid tumors with a tubulin inhibitor payload, and ALE.P03, which targets CLDN1+ tumors with a distinct topoisomerase I inhibitor payload. https://lnkd.in/gJjPHNAQ

2

📢 Pentixapharm AG Acquires Target Discovery Business of Glycotope GmbH, effective July 1st.  This strategic acquisition of the Berlin-based biotech company marks a significant milestone in their mission to develop novel targeted radiopharmaceuticals against a broad range of malignancies. 🌟 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻: • 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼: The deal includes a portfolio of 𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 against multiple oncology targets, 𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗲𝘀, cell banks, a 𝘁𝘂𝗺𝗼𝗿 𝘁𝗮𝗿𝗴𝗲𝘁 𝗱𝗮𝘁𝗮𝗯𝗮𝘀𝗲, and essential equipment.    • 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗜𝗻𝘁𝗲𝗹𝗹𝗲𝗰𝘁𝘂𝗮𝗹 𝗣𝗿𝗼𝗽𝗲𝗿𝘁𝘆: This acquisition broadens the 𝗜𝗣 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 beyond the CXCR4 receptor, 𝗱𝗼𝘂𝗯𝗹𝗶𝗻𝗴 the 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 and expanding business and clinical opportunities.    • 𝗘𝘅𝗽𝗲𝗿𝘁 𝗧𝗲𝗮𝗺: Pentixapharm welcomes an 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝘁𝗲𝗮𝗺 𝗼𝗳 𝟰𝟬 seasoned executives, R&D specialists, and administrators from Glycotope.    • 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗘𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻: Patrik Kehler, former CSO of Glycotope, will join as Pentixapharm's 𝗖𝗦𝗢, and Henner Kollenberg, former CEO of Glycotope, will become the 𝗖𝗵𝗶𝗲𝗳 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗢𝗳𝗳𝗶𝗰𝗲𝗿.    💬 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗣𝗲𝗻𝘁𝗶𝘅𝗮𝗽𝗵𝗮𝗿𝗺'𝘀 𝗟𝗲𝗮𝗱𝗲𝗿𝘀: “Glycotope’s pipeline comprises 𝘀𝗲𝘃𝗲𝗿𝗮𝗹 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲𝘀 that can be 𝘂𝘀𝗲𝗱 𝗶𝗺𝗺𝗲𝗱𝗶𝗮𝘁𝗲𝗹𝘆 for 𝗽𝗿𝗼𝗼𝗳-𝗼𝗳-𝗰𝗼𝗻𝗰𝗲𝗽𝘁 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 as next generation radiopharmaceuticals,” said Dr. Hakim Bouterfa, CEO of Pentixapharm AG. “We look forward to 𝗺𝗮𝘅𝗶𝗺𝗶𝘇𝗶𝗻𝗴 𝘁𝗵𝗲 𝘀𝘆𝗻𝗲𝗿𝗴𝘆 of Pentixapharm’s know-how and Glycotope’s target discovery for the 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝗼𝗳 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 in both diagnostics and therapeutic applications.” “The transaction 𝘀𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻𝘀 our 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 and administrative capacities, facilitating a 𝘀𝗲𝗮𝗺𝗹𝗲𝘀𝘀 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 to the 𝗙𝗿𝗮𝗻𝗸𝗳𝘂𝗿𝘁 𝗦𝘁𝗼𝗰𝗸 𝗘𝘅𝗰𝗵𝗮𝗻𝗴𝗲,” noted 𝗗𝗿. 𝗔𝗻𝗱𝗿𝗲𝗮𝘀 𝗘𝗰𝗸𝗲𝗿𝘁, Chairman of the Supervisory Board of both Pentixapharm and Eckert & Ziegler SE. This acquisition positions Pentixapharm to develop 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 by leveraging Glycotope’s 𝘂𝗻𝗶𝗾𝘂𝗲 𝗚𝗹𝘆𝗰𝗼𝗧𝗮𝗿𝗴𝗲𝘁𝘀—tumor-associated 𝗰𝗮𝗿𝗯𝗼𝗵𝘆𝗱𝗿𝗮𝘁𝗲 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲𝘀 with 𝘀𝘂𝗽𝗲𝗿𝗶𝗼𝗿 𝘁𝘂𝗺𝗼𝗿-𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰𝗶𝘁𝘆. These advancements have the potential to close the treatment gap for many solid tumors, enhancing both diagnostic and therapeutic applications. 🔗 Learn More: https://lnkd.in/eCXh35Nw #NuclearMedicine #Radiopharmaceuticals #Acquisition #PrecisionMedicine  

106

📢 Breaking news! Martinsried-based start-up SciRhom has raised EUR 63 million in a Series A financing round to advance its iRhom2-targeted antibody therapies against autoimmune diseases. ➡ https://lnkd.in/ejivNSTR SciRhom is developing novel antibodies that simultaneously block multiple pro-inflammatory signaling pathways and promote immune tolerance, which could significantly help patients with autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease and lupus nephritis. The first clinical trial with the promising candidate SR-878 is expected to start in the second half of 2024. 👏 Great succcess! Congratulations! This round was led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital and Wellington Partners, with participation from Bayern Kapital and existing investors such as HTGF | High-Tech Gründerfonds and PhiFund Ventures. 📸 Picture: The SciRhom managment team: COO Dr. Jens Ruhe, CEO Dr. Jan Poth and CSO Dr. Matthias Schneider (from left) © SciRhom #Biotech #Autoimmunetherapies #SciRhom #iRhom2 #Martinsried #rheumatoidearthritis #inflammatoryboweldisease #lupusnephritis

134

2 Kommentare

𝐒𝐑𝐓𝐃 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 𝐒𝐞𝐞𝐝 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐭𝐨 𝐃𝐫𝐢𝐯𝐞 𝐒𝐢𝐝𝐞-𝐄𝐟𝐟𝐞𝐜𝐭-𝐅𝐫𝐞𝐞 𝐑𝐍𝐀 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐭𝐨 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐝 𝐂𝐞𝐥𝐥𝐬 Emerging from Germany’s biotech landscape, SRTD Biotech has concluded a significant seed funding round led by HTGF | High-Tech Gründerfonds, with added backing from prominent business angels. This investment will propel the development of SRTD’s pioneering RNA therapeutics, which are designed to activate only within diseased cells, aiming to reduce adverse effects. Built on a proprietary platform, SRTD’s approach centers on 𝑠𝑒𝑙𝑒𝑐𝑡𝑖𝑣𝑒𝑙𝑦 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑒𝑑 𝑅𝑁𝐴𝑠 (seRNAs), a technology that enhances treatment effectiveness while reducing risk to healthy cells. Initially focused on liver cancer, the platform also holds potential for a wide array of applications, including autoimmune disorders. With highly targeted therapies, SRTD aims to set new benchmarks in RNA-based treatments. This funding will accelerate SRTD’s goal of bringing liver cancer treatment candidates into clinical development within three years, positioning the company as a valuable partner for the pharmaceutical and biotech sectors and further establishing seRNAs as an innovative therapeutic option across diverse medical fields. BIO.NRW extends warm congratulations to SRTD Biotech on this achievement and looks forward to the innovative strides they will bring to the field of RNA therapeutics 👏 Picture courtesy: SRTD Biotech

26

TOP 100 Swiss Startup ImmunOs Therapeutics AG raises USD 11 million to continue developing first-in-class therapeutics for the treatment of cancer. Read the full article: https://lnkd.in/da58Vt55 The funding will support ongoing clinical trials, including testing the drug both on its own and in combination with Merck’s well-known cancer therapy, KEYTRUDA®. About: ImmunOs Therapeutics AG is leading the next generation of immunotherapies by fast-tracking new discoveries to enhance combination therapies with novel human immunomodulatory proteins that have a role in both the innate and adaptive immune system for cancer treatment. #TOP100SSU #SwissStartups

22

2 Kommentare

🚀 Any news from #biotechnology in #Bavaria? Surely! 📚 We're proud to be mentioned in the latest report "𝗕𝗜𝗢𝗧𝗘𝗖𝗛 𝗜𝗡 𝗕𝗔𝗩𝗔𝗥𝗜𝗔 – 𝗜𝗡𝗖𝗨𝗕𝗔𝗧𝗜𝗡𝗚 𝗦𝗖𝗜𝗘𝗡𝗖𝗘 𝗙𝗢𝗥 𝗛𝗘𝗔𝗟𝗧𝗛 ," by BioM Biotech Cluster Development GmbH, highlighting the key players and innovations driving the industry forward. 👇 Click below for all the latest insights!

6

🎤 Highlight from Festival of Biologics (FOB) 2024 🎤 Last week, Professor Dr. Stefan Dübel, Co-Founder and Chief Technology Officer of MabSwitch Inc, delivered an insightful presentation at Festival of Biologics in Basel, Switzerland. Dr. Dübel discussed how regulating antibody affinity can significantly enhance T-cell-based immunotherapies—a critical innovation in the fight against cancer and autoimmune diseases. 🔬💡 We’re excited about the future of these therapies and grateful to everyone who attended and engaged in meaningful discussions. Stay tuned for more exciting updates from MabSwitch Inc! #SwitchableAntibodies #TCellTherapy #BiotechInnovation #Immunotherapy #CancerResearch #MabSwitch #AutoimmuneResearch #FOB

82

2 Kommentare

USD 90 million for next-gen multifunctional precision immunotherapies: TOP 100 Swiss Scale-up Bright Peak Therapeutics secures its Series C. Congratulations to the team - best of success onwards! https://lnkd.in/eAGeqdfj About: Bright Peak is rapidly advancing a robust portfolio of next-generation, multi-functional, cytokine-based immunotherapies for the treatment of patients with cancer and autoimmune disease. The company accomplishs this by leveraging our world-class protein engineering capabilities and our unique cell-free technology platform to chemically synthesize and conjugate novel protein therapeutics that reflect state-of-the-art insights into cytokine and immune checkpoint biology. The financing round was led by Johnson & Johnson Innovation JJDC Inc, with new investors Venrock, KB Investment, and Northleaf Capital Partners also contributing. Returning investors include founding investor Versant Ventures, along with Fidelity Management And Research Company, RA Capital Management, Qatar Investment Authority, The Invus Group, and Alexandria Venture Investments. Bright Peak Therapeutics was ranked among the TOP 100 Swiss Startups in 2022. #TOP100SSU #SwissStartups

33

Mainz BioMed (@mainzbio), a biotech firm specializing in clinical laboratory tests, is making strides in early disease detection and prevention. According to Bill Caragol, the company's CFO, their genetic and genomic tests can reveal patients' unique genetic profiles, enabling doctors to tailor treatments more effectively and ushering in an era of personalized medicine. Caragol recently shared promising data from recent trials, highlighting the potential of their tests to detect cancer and chronic conditions at an early stage. Early detection is crucial, as it allows patients to receive timely treatment and improve their chances of survival. As diagnostic technology advances, Mainz BioMed aims to save lives and reduce healthcare costs through early disease identification. Their innovative approach could revolutionize how we approach cancer and chronic condition management. #biotechnology #cancerprevention #personalmedicine

1

📰 Read insights from our CEO, Manfred Ruediger, and CMO, Germo Gericke, in Nature Biotech's recent article, titled ‘Precision radiation opens a new window on cancer therapy.’   Manfred and Germo spoke with Melanie Senior and gave their thoughts on the emerging #radiopharma field and #Ariceum's Iodine-123 labelled PARP inhibitor for patients with recurrent #glioblastoma. Read more about Ariceum's first-in-class Iodine-123 labelled PARP inhibitor here https://bit.ly/45wokzV as it prepares to commence a phase 1 trial in the UK in June 2024!   #lifesciences #biotech #radiopharmaceuticals #ATT001 #ATT002 #satoreotide

97

Great news from Boston: Venture Leader Biotech Allegria Therapeutics, currently with the Swiss National Startup Team in the US, announces USD 3.5 million in seed funding raised. Applause on the deal to Maria Van Dongen and her ambitious team! https://lnkd.in/gZJJPbvM The funding was provided by Forty51 Ventures. About: Allegria Therapeutics' R&D activities focus on mast cells as mediators of allergy and inflammatory diseases, a class of indications that constitutes an increasing burden worldwide. More and more patients suffer from these conditions' impact on their quality of life. The associated socioeconomic burden is huge, and despite the growing medical need, the treatment options are still notoriously limited with overall poor outcomes. For more information and updates on Allegria Therapeutics and the Venture Leaders Biotech 2024, follow #VLeadersBioech on social media and on https://lnkd.in/dsdBqy2E. Should you be in Boston tomorrow, get your invitation to join us at Swissnex for the the Biotech Pitchfest https://lnkd.in/dfNJrfs5 and meet the full Team. This year's Venture Leaders Biotech program is co-organized by Venturelab and Swissnex in Boston and New York and supported by Debiopharm, EPFL, ETH Zürich, Hansjörg Wyss, Kellerhals Carrard Startup & VC Desk, Novartis, Swiss Biotech Association and VISCHER. #VLeadersBiotech #SwissStartups

26

1 Kommentar

Araris Biotech AG is one of seven ADC companies selected by Clarivate in June this year as 2024 ADC companies to watch. This company is developing novel ADCs with two oncolytic payloads (dual-payload). Araris is aiming to take its first multi-payload ADC, which uses a combination of payloads including topoisomerase 1 inhibitor (TOP1i) payloads, to the clinic sometime in late 2025. Philipp Spycher, a cofounder and Chief Scientific Officer of Araris was interviewed in this insightful interview article. You may know from this article how Araris’ technology works. Chinese Antibody Society is an independent non-profit, non-government global professional organization with focus upon antibody-based therapeutics. Our society’s official journal, Antibody Therapeutics is an international peer-reviewed, open access journal published by Oxford University Press, and is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal. https://lnkd.in/gsTu_U2 #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics #adc #adcs #antibodydrugconjugates #antibodydrugconjugate

30

+++ 𝗤𝟭 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝟮𝟬𝟮𝟰 𝗮𝗻𝗱 𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝘂𝗽𝗱𝗮𝘁𝗲 +++ We started the year with good progress across our oncology pipeline and our commercialization activities. Some key events: 🔬 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆: We and our collaboration partner Duality Biologics dosed the first patient in a Phase 3 clinical trial with our #ADC candidate BNT323/DB-1303 in breast cancer patients, advancing towards BioNTech’s goal of ten or more potentially registrational trials running by the end of 2024. 🩹 𝗖𝗢𝗩𝗜𝗗-𝟭𝟵: We are focusing on preparing for variant-strain adaptation of our COVID-19 vaccine to be ready for a commercial launch ahead of the upcoming 2024/2025 vaccination season, pending approvals. 🌎 𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗿𝗲𝗮𝗱𝗶𝗻𝗲𝘀𝘀: We appointed our General Manager Fatma Ocak for the U.S. in line with our commercial preparations to drive our first expected global #oncology product launch. 𝗟𝗶𝗻𝗸 𝘁𝗼 𝗣𝗥 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀: https://lnkd.in/ePDQiHbH  

551

2 Kommentare

I wrote on 23 August 2021 that the European Commission was wrong in pursuing the Illumina/Grail merger, for many more reasons than an obvious lack of jurisdiction over the case, as CJEU decided yesterday - https://lnkd.in/dtrP_84M. This case represents a blatant abuse of power and responsibility for those involved must be engaged. So, I expect a mea culpa, followed by a letter of resignation from Ms. Vestager. But this is not all, Illumina received a fine of almost half billion Euros for an alleged ”gun-jumping”, it has been forced to divest Grail (it still has a minority package thou), incurring a loss of more than 7 billion USD (!!) and had significant legal cost in pursuing a futile legal battle, only because the enforcement of the competition rules in the EU is so rotten that one person can determine the outcome of any action, without proper oversight or balancing of the powers in the form of a true collective decision in such important matters. What happened in Illumina shatters all the good things the European Commission did and puts a spotlight on the very weak enforcement of the EU competition rules on the European pharma companies, which cartelise and have secret deals with governments in the EU, while the European Commission turns a blind eye. #illumina https://lnkd.in/dxVSvANd

4

PIRCHE and TCBalance Biopharmaceuticals GmbH Announce Collaboration and Partnering Agreement on regulatory T Cell Therapy Research and Development. Berlin-based tcbalance Biopharmaceuticals GmbH and Munich/Utrecht-based Pirche Digital Diagnostics AG, have agreed to enter into a strategic research collaboration and partnering agreement. Together, the two leading European technology companies aim to advance the development of potentially ground-breaking cell therapeutics based on regulatory T cells. Regulatory T cells (Treg) are a small subpopulation of T cells that have the task of attenuating undesired and excessive reactions of the body’s immune system — without Treg we are not able to survive, they are also called the “peace-makers” of the immune system. Immunological disorders such as autoimmune diseases may have a major impact on patient’s life. A hallmark of such diseases is an imbalance within the immune system. Conventional therapeutic approaches to immune diseases generally do not readjust the immune balance which reduces the sustainability of these approaches and often require a long, even lifelong treatment. Numerous data generated worldwide from preclinical model systems show that cell therapy with activated Treg may lead to impressive and lasting therapeutic effects and first early clinical studies point toward the feasibility and safety of such a cell-based therapy and provide promising hints for sustainable effectiveness (e.g., Roemhild et al. BMJ 2020). Pirche founder and CEO Thomas Klein is delighted with this partnering agreement: “The exclusive Pirche technology will be used for the first time in the development of allogeneic cell therapies and the “off-the-shelf” selection using immune risk profiles in the areas of severe diseases. This is a significant step for Pirche towards the wider business of digital therapeutics.” For more information please read here: https://lnkd.in/ekkdSfQH

12

The Swiss Venture Capital Report's half year update makes for interesting reading 🗞 Biotech performed well and with surveyed investors reporting ‘dry powder’; i.e. funds available for investment, we hope this trend is set to continue. iOnctura's Series B of 76.5M CHF was the second largest of the period 👏 👉 Read the full report here: https://lnkd.in/eYpAudxe

18